PRS-352

PRS-352 is a recombinant bispecific fusion protein developed as an immunotherapy for cancer. It is composed of two functional domains: a PD-L1 (programmed death-ligand 1) blocking moiety and an Anticalin protein that acts as an agonist of OX40 (also known as TNFRSF4). The drug is designed to stimulate T lymphocytes, particularly CD4+ T cells, in a PD-L1-dependent manner. This dual mechanism enables both the blockade of immune checkpoint inhibition via PD-L1 and the activation of co-stimulatory signaling through OX40, potentially enhancing anti-tumor immune responses. Preclinical studies have shown that PRS-352 can strongly stimulate human CD4+ T cells with superior activity compared to clinical-stage OX40 agonists[5]. The drug was initially developed by Pieris Pharmaceuticals and has been further advanced in collaboration with Servier[6].

Other names

S095025S-095025S 095025